Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cognition Therapeutics, Inc.
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
June 16, 2026
Cognition Therapeutics Participating in Upcoming Investor Conferences
June 1, 2026
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
May 31, 2026
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
May 30, 2026
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
May 29, 2026
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
May 24, 2026
Cognition Therapeutics CEO Issues Letter to Shareholders
May 22, 2026
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
May 22, 2026
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
May 22, 2026
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
May 20, 2026
1
2
Next Page
→